Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.

Molecular cancer - 24 May 2014

Hirschi Benjamin, Gallmeier Eike, Ziesch Andreas, Marschall Maximilian, Kolligs Frank T

Abstract excerpt

BACKGROUND: Colorectal cancers carrying the B-Raf V600E-mutation are associated with a poor prognosis. The purpose of this study was to identify B-RafV600E-mediated traits of cancer cells in a genetic in vitro model and to assess the selective sensitization of B-RafV600E-mutant cancer cells towards therapeutic agents. METHODS: Somatic cell gene targeting was used to generate subclones of the colorectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colon
Share to Culture Media, Serum-Free

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Oximes

Source

Open in PubMed Open full text

Identifiers

PMID: 24885690
DOI: 10.1186/1476-4598-13-122
PMCID: PMC4035728

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.PMID 24885690Read ↗

BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Semantic proximity Read ↗

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceSemantic proximity Read ↗

[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].Semantic proximity Read ↗

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.Semantic proximity Read ↗

B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.Semantic proximity Read ↗

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.Semantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.Semantic proximity Read ↗

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.Semantic proximity Read ↗

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.